Medical Policy
Hip Resurfacing

Table of Contents
• Policy: Commercial
• Coding Information
• Information Pertaining to All Policies
• Policy: Medicare
• Description
• References
• Authorization Information
• Policy History

Policy Number: 046
BCBSA Reference Number: 7.01.80
NCD/LCD: N/A

Related Policies
• Surgical Treatment of Femoroacetabular Impingement, #145

Policy
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

Metal-on-metal total hip resurfacing with a device system approved by the U.S. Food and Drug Administration may be considered MEDICALLY NECESSARY as an alternative to total hip replacement when the patient:
• Is a candidate for total hip replacement; AND
• Is likely to outlive a traditional prosthesis; AND
• Does not have a contraindication* for total hip resurfacing.

*The U.S. Food and Drug Administration lists several contraindications for total hip resurfacing. These contraindications include, but are not limited to, the following:
• Bone stock inadequate to support the device due to:
  o severe osteopenia or a family history of severe osteoporosis or severe osteopenia
  o osteonecrosis or avascular necrosis with more than 50% involvement of the femoral head
  o multiple cysts of the femoral head (>1 cm)
• Skeletal immaturity
• Vascular insufficiency, muscular atrophy, or neuromuscular disease severe enough to compromise implant stability or postoperative recovery
• Known moderate-to-severe renal insufficiency
• Severely overweight
• Known or suspected metal sensitivity
• Immunosuppressed or receiving high doses of corticosteroids
• Females of child bearing age due to unknown effects on the fetus of metal ion release.
Partial hip resurfacing with a Food and Drug Administration-approved device may be considered **MEDICALLY NECESSARY** in patients with osteonecrosis of the femoral head who have one or more contraindications for metal-on-metal implants and meet all of the following criteria:

- The patient is a candidate for total hip replacement; **AND**
- Is likely to outlive a traditional prosthesis; **AND**
- The patient has known or suspected metal sensitivity or concern about potential effects of metal ions; **AND**
- There is no more than 50% involvement of the femoral head; **AND**
- There is minimal change in acetabular cartilage or articular cartilage space identified on radiography.

All other types and applications of hip resurfacing are considered **INVESTIGATIONAL**.

**Prior Authorization Information**

**Inpatient**
- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

**Outpatient**
- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

<table>
<thead>
<tr>
<th>Commercial Managed Care (HMO and POS)</th>
<th>Outpatient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior authorization is required.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Commercial PPO and Indemnity</th>
<th>Outpatient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior authorization is required.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medicare HMO Blue&lt;sup&gt;SM&lt;/sup&gt;</th>
<th>Outpatient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior authorization is required.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medicare PPO Blue&lt;sup&gt;SM&lt;/sup&gt;</th>
<th>Outpatient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior authorization is required.</td>
<td></td>
</tr>
</tbody>
</table>

**CPT Codes / HCPCS Codes / ICD Codes**

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

*The following codes are included below for informational purposes only; this is not an all-inclusive list.*

The above **medical necessity criteria MUST be met** for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

**CPT Codes**
There is no specific CPT code for this service.

**HCPCS Codes**

<table>
<thead>
<tr>
<th>HCPCS codes:</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S2118</td>
<td>Metal-on-metal total hip resurfacing, including acetabular and femoral components</td>
</tr>
</tbody>
</table>

**ICD-10 Procedure Codes**

<table>
<thead>
<tr>
<th>ICD-10-PCS procedure codes:</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SU90BZ</td>
<td>Supplement Right Hip Joint with Resurfacing Device, Open Approach</td>
</tr>
</tbody>
</table>
Description
Hip resurfacing is an alternative to total hip arthroplasty (THA; also known as total hip replacement) for patients with advanced arthritis of the hip. Total hip resurfacing (THR) describes the placement of a shell that covers the femoral head together with implantation of an acetabular cup. Partial hip resurfacing is considered a treatment option for avascular necrosis with collapse of the femoral head.

THR has been investigated in patients with osteoarthritis, rheumatoid arthritis, and advanced avascular necrosis as an alternative to THA, particularly in young active patients who would potentially outlive a total hip prosthesis. Therefore, hip resurfacing could be viewed as a time-buying procedure to delay the need for a THA. Proposed advantages of THR compared with THA include preservation of the femoral neck and femoral canal, thus facilitating revision or conversion to a THR, if required. In addition, the resurfaced head is more similar in size to the normal femoral head, thus increasing the stability and decreasing the risk of dislocation compared with THA.

THR has undergone various evolutions, with modifications in prosthetic design and composition and implantation techniques. For example, similar to total hip prostheses, the acetabular components of THR have been composed of polyethylene. However, over time it became apparent that device failure was frequently related to the inflammatory osteolytic reaction to polyethylene debris wear particles. Metal acetabular components have since been designed to improve implant longevity. Sensitivity to wear particles from metal-on-metal chromium and cobalt implant components are of increasing concern.

Summary
Hip resurfacing is an alternative to total hip arthroplasty (THA; also known as hip replacement) for patients with advanced arthritis of the hip. Total hip resurfacing (THR) describes the placement of a shell that covers the femoral head together with implantation of an acetabular cup in patients with painful hip joints. Partial hip resurfacing is considered a treatment option for avascular necrosis with collapse of the femoral head. Available prostheses are metal-on-metal devices.

For individuals who have an indication for hip replacement who would outlive a traditional prosthesis and have no contraindication for hip resurfacing who receive a metal-on-metal total hip resurfacing device or a partial hip resurfacing device, the evidence includes two randomized controlled trials, numerous large observational studies, large registry studies, and systematic reviews. The relevant outcomes are symptoms, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related morbidity. The efficacy of THR performed with current techniques is similar to that for THA over the short-to-medium term, and THR may permit easier conversion to a THA for younger patients expected to outlive their prosthesis. Based on potential ease of revision of THR compared with
THA, current evidence supports conclusions that hip resurfacing presents a reasonable alternative for active patients who are considered too young for THA when performed by surgeons experienced in the technique. The literature on adverse events (e.g., metallosis, pseudotumor formation, implant failure) is evolving as longer follow-up becomes available. Due to the uncertain risk with metal-on-metal implants, the risk-benefit ratio needs to be considered carefully on an individual basis. In addition, emerging evidence has suggested an increased risk of failure in women, possibly due to smaller implant size. Therefore, these factors should also be considered in the overall patient evaluation for THR, and patients should make an informed choice with their treating physicians. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have an indication for hip replacement who would outlive a traditional prosthesis and have no contraindication for hip resurfacing who receive partial hip resurfacing device, the evidence includes two randomized controlled trials, numerous large observational studies, large registry studies, and systematic reviews. The relevant outcomes are symptoms, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related morbidity. Therefore, these factors should also be considered in the overall patient evaluation for THR, and patients should make an informed choice with their treating physicians. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Policy History

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/2018</td>
<td>Clarified coding information.</td>
</tr>
<tr>
<td>9/2017</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
<tr>
<td>11/2015</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
<tr>
<td>8/2015</td>
<td>Added coding language.</td>
</tr>
<tr>
<td>5/2014</td>
<td>Updated Coding section with ICD10 procedure and diagnosis codes. Effective 10/2015.</td>
</tr>
<tr>
<td>12/2013</td>
<td>Removed ICD-9 diagnosis codes as the policy requires prior authorization. Added ICD-9 CM-procedure code 00.75 as it meets the intent of the policy.</td>
</tr>
<tr>
<td>6/2010</td>
<td>BCBS Association National Policy Review Policy updated to address partial hip resurfacing when medical criteria are met.</td>
</tr>
<tr>
<td>7/2009</td>
<td>Reviewed - Medical Policy Group - Orthopedics, Rehabilitation Medicine, and Rheumatology. No changes to policy statements.</td>
</tr>
<tr>
<td>10/1/2008</td>
<td>Coding section updated to reflect new HCPCS Level II code for hip resurfacing.</td>
</tr>
<tr>
<td>7/2008</td>
<td>Reviewed - Medical Policy Group – Orthopedics, Rehabilitation Medicine, and Rheumatology. No changes to policy statements.</td>
</tr>
</tbody>
</table>
Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

- Medical Policy Terms of Use
- Managed Care Guidelines
- Indemnity/PPO Guidelines
- Clinical Exception Process
- Medical Technology Assessment Guidelines

References


